Description
Why Dexcom’s CMS Decision Matters More Than First Quarter Strength!
Dexcom, Inc. reported first quarter 2026 revenue of $1.19 billion, marking a 15% increase year-over-year and 12% organic growth. This performance was driven primarily by strong global demand for continuous glucose monitoring (CGM) products, supported by broader access, new product launches—particularly the G7 15 Day system—and sustained growth in the active user base. U.S. revenues grew 11% to $832 million, with notable gains in the type 2 diabetes market, especially among non-insulin users benefiting from expanding commercial coverage, including a new reimbursement win with Prime Therapeutics expected to cover over 7 million type 2 non-insulin lives by year-end. International revenues increased 26% to $360 million, reflecting broad growth across core markets and benefits from recent reimbursement expansions. Gross profit expanded to $757.4 million, with a gross margin of 63.5%, up significantly from 57.
